HER2/neu as a predictive factor in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Translational Research

Background:

• Breast cancer research focuses on identifying predictive markers for targeted therapies.
• HER2/neu (Human Epidermal growth factor Receptor 2) is a key transmembrane tyrosine kinase receptor investigated for its role in breast cancer.
• HER2 overexpression is linked to poorer survival outcomes in breast cancer patients.

Purpose of the Study:

• To review the predictive value of HER2 in breast cancer treatment response.
• To explore mechanisms of sensitivity and resistance to HER2-targeted and cytotoxic therapies.
• To outline future research directions for HER2-based therapeutic strategies.

Main Methods:

• Review of existing literature on HER2 in breast cancer.
• Analysis of retrospective and prospective clinical trial data.
• Examination of molecular mechanisms underlying HER2 function and therapeutic targeting.

Main Results:

• HER2 overexpression is associated with decreased disease-free and overall survival.
• Antibodies targeting HER2 have shown efficacy in advanced breast cancer with HER2 overexpression.
• Combination therapies involving HER2 antibodies and cytotoxic drugs improve survival in metastatic breast cancer.

Conclusions:

• HER2 is a significant predictive marker for response to specific breast cancer therapies, particularly antibody-mediated treatments.
• The role of HER2 in predicting response to hormone therapy and conventional cytotoxic drugs requires further prospective validation.
• Targeting HER2 offers a promising strategy for improving survival in early and advanced breast cancer.